专业制药公司Nutriband Inc.宣布与Innomedica达成战略合作，双方签署了针对哥斯达黎加市场的独家分销协议。根据协议条款，Innomedica将获得Nutriband旗下Aversa芬太尼透皮贴片产品及全系列运动贴布在哥斯达黎加地区的独家经销权。
此次合作标志着Nutriband在拓展拉丁美洲市场战略布局中的重要一步。Aversa作为采用专利防滥用技术的芬太尼制剂，能有效降低药物滥用风险；而运动贴布系列产品则涵盖运动防护、肌肉支撑等专业领域。通过Innomedica在当地成熟的医药分销网络，这些产品将更快触达哥斯达黎加医疗机构和零售终端。
协议执行后，Innomedica将全面负责相关产品在哥斯达黎加的市场推广、渠道管理和合规运营。双方表示将共同推进产品注册流程，预计首批产品将于2024年内完成市场准入。这项合作不仅强化了Nutriband的全球化商业版图，也为中美洲地区患者带来了更先进的疼痛管理和运动医疗解决方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.